Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 11.51M | 11.69M | 9.76M | 11.96M | 4.33M | 9.38M |
Gross Profit | 9.47M | 9.73M | 7.72M | 9.94M | 2.00M | 6.11M |
EBITDA | -38.48M | -36.66M | -33.13M | -33.38M | -42.35M | -28.74M |
Net Income | -39.73M | -38.49M | -41.30M | -47.45M | -60.25M | -36.79M |
Balance Sheet | ||||||
Total Assets | 51.46M | 53.42M | 50.76M | 47.45M | 53.27M | 42.84M |
Cash, Cash Equivalents and Short-Term Investments | 5.69M | 8.00M | 6.47M | 5.47M | 17.05M | 8.09M |
Total Debt | 38.34M | 36.53M | 37.09M | 34.84M | 29.36M | 16.21M |
Total Liabilities | 50.63M | 46.93M | 45.87M | 48.81M | 41.41M | 25.64M |
Stockholders Equity | 1.78M | 9.77M | 4.96M | -657.00K | 11.61M | 17.20M |
Cash Flow | ||||||
Free Cash Flow | -29.87M | -29.61M | -33.24M | -34.78M | -34.98M | -15.29M |
Operating Cash Flow | -29.65M | -29.38M | -33.24M | -33.10M | -34.97M | -15.28M |
Investing Cash Flow | -231.00K | -231.00K | 1.23M | -1.68M | -6.00K | -7.00K |
Financing Cash Flow | 23.90M | 31.20M | 34.23M | 23.18M | 43.94M | 19.49M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.82B | -0.16 | -39.78% | 2.19% | 21.38% | -1.56% | |
42 Neutral | $3.68M | ― | -296.91% | ― | 15.95% | 92.33% | |
39 Underperform | $15.86M | ― | -402.19% | ― | ― | 59.81% | |
39 Underperform | $5.25M | ― | -285.78% | ― | 120.67% | -456.33% | |
28 Underperform | $3.32M | ― | -49.58% | ― | ― | 67.95% | |
28 Underperform | $4.30M | ― | -340.81% | ― | ― | 94.99% | |
15 Underperform | $3.63M | ― | -231.27% | ― | ― | 85.78% |
On August 19, 2025, Jaguar Health held its Annual Meeting of Stockholders, where seven proposals were approved, including the election of directors and amendments to stock plans. The company also announced promising results from trials of crofelemer for gastrointestinal conditions and outlined plans for regulatory pathways and business development partnerships, potentially impacting its market strategy and stakeholder interests.
On August 14, 2025, Jaguar Health, Inc. announced an amendment to its At the Market Offering Agreement, extending Lucid Capital Markets, LLC’s role as a Manager until December 31, 2025. This amendment, filed with the SEC, ensures that Lucid will continue its managerial role alongside Ladenburg Thalmann & Co. Inc. until the end of 2025, after which Ladenburg will become the sole Manager unless further extended.
On June 27, 2025, Jaguar Health, Inc. entered into exchange agreements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC, issuing Series M Preferred Stock in exchange for reductions in outstanding royalty interests. This strategic move allows Jaguar Health to manage its financial obligations while offering stakeholders a structured investment opportunity through the Series M Preferred Stock, which includes specific rights and limitations, impacting the company’s capital structure and market positioning.
On June 24, 2025, Jaguar Health, Inc. announced an extension of the maturity date for $2.57 million of convertible promissory notes from its March 2025 bridge financing, now maturing on January 30, 2026. This extension, involving participation from the company’s CEO, board members, and other investors, aims to support Jaguar’s strategic goals, including partnerships for non-dilutive funding and advancing development programs for crofelemer in treating various conditions.
On May 20, 2025, Jaguar Health, Inc. entered into a securities purchase agreement for a registered direct offering of 246,306 shares of common stock at $6.09 per share, expected to raise approximately $1.5 million. The offering, set to close around May 22, 2025, includes a concurrent private placement of unregistered warrants to purchase up to 492,612 shares. The proceeds will be used for corporate purposes, including working capital and debt repayment. H.C. Wainwright & Co. acted as the placement agent, receiving a fee and warrants as compensation. This move is part of Jaguar’s strategy to strengthen its financial position and support its operational and development goals.